Research programme: selective androgen receptor antagonists - Biogen Idec
Alternative Names: CNF 316Latest Information Update: 19 May 2006
At a glance
- Originator Biogen Idec
- Class
- Mechanism of Action Heat-shock protein inhibitors; Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec
- 19 Dec 2001 Preclinical development for Prostate cancer in USA (Unknown route)